ANATDEL
Medical 3D printing solution
Software · On PremiseCompany source
Company profile
About MEDICALIP Co., Ltd
MEDICALIP Co., Ltd. is a pioneering healthcare AI company founded in 2015 and headquartered in Seoul, South Korea. The company develops advanced medical imaging analysis solutions that integrate artificial intelligence, 3D technologies (including 3D printing, CAD/CAM, AR/VR), and digital twin capabilities to transform medical diagnosis, education, and patient care. MEDICALIP's core technology focuses on accurate medical image segmentation and analysis, detecting body components and lesions from medical images using AI to extract quantitative data such as volume and area measurements. This enables precision medicine through disease prediction and patient progress monitoring. The company's product portfolio includes DeepCatch for comprehensive body composition evaluation from CT scans, DeepCatch X for thoracic aortic aneurysm monitoring, DeepFore for hepatocellular carcinoma risk prediction with 89% accuracy, MEDIP Pro as an all-in-one medical imaging solution, and MEDIP Box for immersive VR-based anatomy education in the medical metaverse. MEDICALIP has achieved significant regulatory milestones including FDA Class II certification, MFDS approvals in South Korea, CE/MDD certification in Europe, MHRA certification in the UK, and NMPA certification in China. The company serves health systems, medical education institutions, and healthcare providers globally, with offices in South Korea, the United States, and China. As an NVIDIA Inception Premier Partner, MEDICALIP is advancing the integration of digital twin technology into medical practice and education, targeting a KOSDAQ IPO in the first half of 2027.
Company description MEDICALIP Co., Ltd official website
Primary marketMedical Imaging & Radiology
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at MEDICALIP Co., Ltd?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Bone density issues
- Brain tumors
- Chronic hepatitis B
- COVID-19 pneumonia
- Hepatocellular carcinoma
- Kidney cancer
- Muscle loss
- Thoracic aortic aneurysm
- Visceral fat disorders
Who it serves
- Academic Medical Centers
- Health Systems
- Hospitals
- Medical Education Institutions
- Research Institutions
Deployment & integration
Cloud Saas · On Premise deployment with recorded integration context.
Geographic context
MarketsChina · Europe · Germany · Japan · South Korea · Spain · Sweden · United Kingdom · United States
Company sourceOfficial website
Company milestones
Platform expansion
July 2025: Commenced supply of DeepCatch X to 17 KAHP branches. June 2025: DeepFore selected as 'Selection of the Month' and featured on Journal of Hepatology cover. May 2025: DeepFore received MFDS Class III approval. April 2025: MEDIP Pro obtained NMPA certification in China (first among domestic AI companies) and supplied to PUMC Hospital. March 2025: DeepFore Recur received MFDS Class III approval (first in liver cancer field). Announced transformation into AI Digital Twin Platform Company targeting KOSDAQ IPO in H1 2027.
Partnerships
Recorded partners
- Amazon Web Services (AWS)
- Chungnam National University Hospital
- DK Medical Systems
- Dong-A Socio Holdings
- Korea Association of Health Promotion (KAHP)
- NVIDIA (Premier Partner in Inception Program)
- PUMC Hospital (China)
- Seoul National University
- Seoul National University Bundang Hospital
- Yonsei University College of Dentistry
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
DeepCatch
Comprehensive whole-body composition analysis from CT scans for healthy longevity evaluation
Software · Cloud SaaSCompany source
DeepCatch X
Fast-track aneurysm detection and monitoring from chest X-rays
Software · Cloud SaaSCompany source
DeepFore
World-leading hepatocellular carcinoma risk prediction with 89% accuracy
Software · Cloud SaaSCompany source
DeepFore Recur
Liver cancer recurrence prediction solution
Software · Cloud SaaSCompany source
MEDIP Box
Digital anatomy table for immersive medical metaverse education
Platform · On PremiseCompany source
MEDIP Pneumovid
Medical imaging analysis software for pneumonia detection
Software · Cloud SaaSCompany source
MEDIP Pro
All-in-one medical imaging solution for analysis, 3D modeling and digital twin creation
Software · On PremiseCompany source
TiSepX Lung Volumetry
Medical imaging analysis software for lung volumetry
Software · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
No linked records are currently available.
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
DeepCatchK223556 · 510k · Jun 16, 2023
MEDIP PROK191026 · 510k · Nov 7, 2019
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
89% predictive accuracy
DeepFore hepatocellular carcinoma risk prediction
Superior educational efficacy
Virtual anatomy dissection vs traditional cadaver dissection in randomized control study
Korea Association of Health Promotion (KAHP)
Supply of cardiovascular imaging analysis software DeepCatch X to 17 branches for cardiovascular risk screening
Deployment across 17 branches for comprehensive cardiovascular monitoring
PUMC Hospital (China)
First domestic digital healthcare company to supply medical imaging analysis software DeepCatch to major Chinese hospital
First among domestic digital healthcare companies to enter Chinese market with hospital deployment
Seoul National University
Developed 3D digital anatomical education content for medical students using AI and 3D medical image technology, transforming anatomy education into metaverse-based learning
Virtual anatomy dissection's educational efficacy and satisfaction were superior to traditional cadaver anatomy dissection in a subgroup of students
Seoul National University Bundang Hospital
Robotic partial nephrectomy for kidney cancer removal using 3D kidney surgical simulator for patient education and surgical planning
Confirmed successful clinical results with patient-specific 3D kidney models that improved patient understanding of their tumors
Yonsei University College of Dentistry
Revolutionizing anatomical education with virtual anatomy table providing highly accurate 3D images and immersive learning experiences
Enabled students to study anatomy in various scenarios including virtual cases of fetuses and pregnant women without need for actual cadavers
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Sang Joon Park
CEO
Park Geun-joo
Independent Director
06 · Company updates
Updates from MEDICALIP Co., Ltd
Recent articles published on MEDICALIP Co., Ltd's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Medical Imaging & Radiology
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.